Drug intelligence / Profile preview

ebola vaccine + marburg vaccine + lassa vaccine

Development stage
Unknown
Lead developer
Aurobindo Pharma
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

A trivalent viral vector vaccine candidate designed to provide protection against Ebola virus, Marburg virus, and Lassa virus. The vaccine utilizes the VesiculoVax platform, which is based on an attenuated Vesicular Stomatitis Virus (VSV) vector engineered to express the surface glycoproteins of the three target pathogens. By delivering these antigens, the vaccine aims to elicit both neutralizing antibody and cellular immune responses against these high-consequence viral hemorrhagic fevers. Originally developed by Profectus BioSciences, the program was licensed by Emergent BioSolutions for further development and commercialization as part of their strategic focus on public health threats.

Other names
trivalent VesiculoVax vaccineEbola/Marburg/Lassa vaccine
02

Targets

PYG (Glycogen phosphorylase)GPC (Lassa virus glycoprotein complex)Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on ebola vaccine + marburg vaccine + lassa vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ebola vaccine + marburg vaccine + lassa vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call